CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 20-944

CHEMISTRY REVIEW(S)

Anti-inflammatory, Analgesic, and Ophthalmic Drug Products, HFD-550 Review of Chemistry, Manufacturing, and Controls

NDA#: 20-944 REVIEW#1

DATE REVIEWED: November 12, 1998

SUBMISSION TYPE	SUBMIS	SSION DATE USER FEE DATE
Original _	12/19/97	
Amendment 1	2/12/98	(Certify ready for inspection on or after 4/30/98)
Amendment 2	2/23/98	(Claim Categorical Exclusion for EA submission)
Amendment 3	3/20/98	(A new stability testing site, corrections in dissolution
		data and stability results)
Amendment 4	7/16/98	(To provide method validation)
Reviewed: All		

NAME & ADDRESS OF APPLICANT:

Whitehall-Robins, 5 Giralda Farms, Madison, NJ 07940-0871

DRUG PRODUCT NAME

Proprietary:

Advil^R Chewable Tablet

Established:

Ibuprofen

Code Name/#:

Chem.Type/Ther.Class:

Temporary relief of headache, backache, muscular aches, toothache, the minor pain of arthritis, the pain of menstrual cramps, the minor aches and pains associated with the common cold, sore throat, and reduction of fever

PHARMACOL. CATEGORY:

NSAID

DOSAGE FORM:

Chewable Tablet

STRENGTHS:

50 mg and 100 mg

ROUTE OF ADMINISTRATION: Oral

DISPENSED:

__Rx__x_OTC

RELATED DOCUMENTS (if applicable): None

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA AND WEIGHT:

CONSULTS:

The trade name "Advil Chewable Tablet" is found acceptable by Nomenclature Committee. A copy of Nomenclature Committee's recommendation is attached to this review.

Dissolution specification: Acceptable to Biopharm. Copies of the request are attached to this review.

REMARKS:

blisters.
,

ENVIRONMENTAL ASSESSMENT:

100's CR bottle, 100 mg:

Claims Categorical Exclusion for the submission of EA citing 21 CFR 25.31(a) in the amendment dated 2/23/98.

SUPPORTING DOCUMENTS:

This page of the document contains confidential information that will not be included in the redacted portion of the document for the public to obtain.

Conclusions and Recommendations:

	From the chemistry stan	dpoint, the NDA is approvable.	
٢			

151

Bart Ho, Review Chemist

Team Leader, Hasmukh Patel

11-12-98

cc:

Orig. NDA 20-944

HFD-550/Division File

HFD-550/BHo

HFD-550/Cook

HFD-550/Patel

HFD-830/Chi-wan Chen

R/D Init by: Patel

Anti-inflammatory, Analgesic, and Ophthalmic Drug Products, HFD-550 Review of Chemistry, Manufacturing, and Controls

NDA #: 20-944 REVIEW # 2

DATE REVIEWED: December 7, 1998

SUBMISSION TYPE

SUBMISSION DATE

USER FEE DATE

Amendment 5

11/20/98

Subject of this review

NAME & ADDRESS OF APPLICANT:

Whitehall-Robins, 5 Giralda Farms, Madison, NJ 07940-0871

DRUG PRODUCT NAME

Proprietary:

Advil^R Chewable Tablet

Established:

Ibuprofen

Code Name/#:

Chem.Type/Ther.Class:

Temporary relief of headache, backache, muscular aches, toothache, the minor pain of arthritis, the pain of menstrual cramps, the minor aches and pains associated with the common cold, sore throat, and reduction of fever

PHARMACOL. CATEGORY:

NSAID

DOSAGE FORM: Chewable Tablet

STRENGTHS:

50 mg and 100 mg


ROUTE OF ADMINISTRATION: Oral

DISPENSED:

_Rx _x_OTC

RELATED DOCUMENTS (if applicable): None

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA AND WEIGHT:



IBUPROFEN C₁₃H₁₈O₂ 206-28

CONSULTS:

The trade name "Adv A copy of Nomencla	t" is found acceptable by Nomenclatu ecommendation is attached to this rev	nclature Committee. his review.	
Dissolution specifica	tion: Acceptable to review.	Copies of the request are	attached to this
REMARKS:			
EER status: Accep	table. A copy of the	ne EER is attached.	
Method validation:	A copy of method 2/13/98.	i validation was sent	
Expiration dating po	eriod (Proposed):	24 months for bottles, pouches and blisters and 18 months for	blisters.

APPL. RS THIS WAY ON DRIGINAL

Conclusions and Recommendations:

In this submission, the applicant has satisfactorily responded to all the deficiencies and comments noted in chemist's review #1. The applicant has provided adequate information on the chemistry, manufacture and controls of the drug substance and drug product. From the chemistry standpoint, the NDA is recommended for approval.

/S/
/2/7/98
Vispi Bhavnagri, Review/Chemist

Team Leader, Hasmukh Patel

CC

Orig. NDA 20-944 HFD-550/Division File HFD-550/BHo/Bhavnagri HFD-550/Cook HFD-550/Patel HFD-830/Chi-wan Chen R/D Init by: Patel